Chemotherapy-Free Strategy for Platinum-Sensitive Recurrent Ovarian Cancer

The Lancet Oncology- United Kingdom

doi 10.1016/s1470-2045(19)30714-4

Full Text

Abstract

Available in

Categories

Date

December 1, 2019

Authors

Publisher

Elsevier BV

Related search

Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study

Asian Pacific Journal of Cancer Prevention

English

Secondary Cytoreduction Surgery Improves Prognosis in Platinum-Sensitive Recurrent Ovarian Cancer

Journal of Experimental and Clinical Cancer Research

Cancer Research

English

Extending the Platinum‐Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second‐Line Chemotherapy

Cancer Research

English

Restoring Platinum Sensitivity in Recurrent Ovarian Cancer by Extending the Platinum-Free Interval: Myth or Reality?

Cancer Research

English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology

Cancer Research

English

Rechallenge With First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Case Reports in Oncology

English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology

Cancer Research

English

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research

English

Molecular Basis of Chemosensitivity of Platinum Pre-Treated Ovarian Cancer to Chemotherapy

British Journal of Cancer

Cancer Research

English